Porosome Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$3.63M
- Investors
-
1
Porosome Therapeutics General Information
Description
Developer of a drug development platform designed to address diseases caused by secretory defects, including Alzheimer's, cystic fibrosis, and diabetes. The company's platform identifies small molecules for treating diseases and specializes in the development and delivery of next-generation antiviral therapeutics, enabling healthcare professionals to access affordable drugs and treatments.
Contact Information
Website
www.porosome.comCorporate Office
- One Boston Place
- Suite 2603
- Boston, MA 02108
- United States
Corporate Office
- One Boston Place
- Suite 2603
- Boston, MA 02108
- United States
Porosome Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Seed Round | 20-Mar-2026 | $3.63M | Completed | Generating Revenue | ||
| 1. Seed Round | 23-Jun-2022 | Completed | Generating Revenue |
Porosome Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Pref |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Porosome Therapeutics Patents
Porosome Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250339383-A1 | Functional porosome manipulation | Pending | 10-Jul-2024 | ||
| WO-2026015731-A1 | Functional porosome manipulation | Pending | 10-Jul-2024 | ||
| US-20240053354-A1 | Functional porosome manipulation | Pending | 08-Aug-2022 | ||
| US-20240316152-A1 | Functional porosome manipulation | Pending | 08-Aug-2022 | ||
| US-12226431-B2 | Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses | Active | 11-Sep-2021 | A61K31/724 |
Porosome Therapeutics Signals
Porosome Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Private Ventures Group | Venture Capital | Minority |
Porosome Therapeutics FAQs
-
When was Porosome Therapeutics founded?
Porosome Therapeutics was founded in 2021.
-
Where is Porosome Therapeutics headquartered?
Porosome Therapeutics is headquartered in Boston, MA.
-
What is the size of Porosome Therapeutics?
Porosome Therapeutics has 2 total employees.
-
What industry is Porosome Therapeutics in?
Porosome Therapeutics’s primary industry is Biotechnology.
-
Is Porosome Therapeutics a private or public company?
Porosome Therapeutics is a Private company.
-
What is Porosome Therapeutics’s current revenue?
The current revenue for Porosome Therapeutics is .
-
How much funding has Porosome Therapeutics raised over time?
Porosome Therapeutics has raised $3.93M.
-
Who are Porosome Therapeutics’s investors?
Private Ventures Group has invested in Porosome Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process